These are a number of featured articles dealing with the consequences of poor data quality
- Pankevich, DE et al. 2014. “Improving and Accelerating Drug Development for Nervous System Disorders.” Neuron; Volume 84, Issue 3, Pages 546–553
- Cummings, JL et al. 2014. “Alzheimer’s disease drug-development pipeline: few candidates, frequent failures.” Alzheimer’s Research & Therapy, 6:37
- Hay, M et al. 2014. “Clinical development success rates for investigational drugs.” Nature Biotechnology 32, 40–51
- Freedman, LP et al. 2015. “The Economics of Reproducibility in Preclinical Research.” PLoS Biol. 13(6):e1002165.
- Hall, W et al. 2015. “The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?” The Lancet Psychiatry Volume 2, Issue 1, Pages 105–110
- Chalmers, I and Glasziou, P 2009. “Avoidable Waste in the Production and Reporting of Research Evidence.” The Lancet 374(9683):86–89.
- Macleod, MR et al. 2014. “Biomedical research: increasing value, reducing waste.” The Lancet; Volume 383, Issue 9912, Pages 101–104
- Lushington, GH and Chaguturu, R 2015. “A systemic malady: the pervasive problem of misconduct in the biomedical sciences part I: issues and causes.” Drug Discovery World
0 Comments
Leave A Comment